Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Coupang Is a Strong Buy on the Dip Despite Reported Losses

By Chris Lau, InvestorPlace Contributor

Markets sold CPNG stock because of inventory losses related to a fire -- a one-time event that will not slow its long-term growth.

Why Alibaba Stock Is Not Yet Worth Buying

By Chris Lau, InvestorPlace Contributor

BABA stock has been falling after Beijing scrutinized its monopoly position and accepted its contribution to “Common Prosperity.”

Buy Roku as Its Streaming Hours Gear up to Rise Again

By Chris Lau, InvestorPlace Contributor

The ROKU stock selloff is unjustified. Its hours watched declined, but that's a temporary setback, especially with Roku's strong revenue growth.

7 Sagging Software Stocks That Are Ready to Rebound

By Chris Lau, InvestorPlace Contributor

These software stocks could rip higher as investors seek deals from out-of-favor firms in an already expensive market at all-time highs.

Developed World Boosters Offer Big Market for Eventual Novavax Vaccine

By Chris Lau, InvestorPlace Contributor

Novavax’s combination vaccine and its Covid-19 vaccine sales for Q1/2022 in Japan are positive drivers for its revenue in the years ahead.

Load More